Stay away from concomitant use of tucatinib with CYP3A substrates, where by negligible concentration modifications could result in significant or daily life-threatening toxicities. If unavoidable, lessen CYP3A substrate dose according to products labeling. crizotinib raises amounts of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check. Dose reduction ... https://lewisn036txb4.blogoxo.com/profile